Replicor to update analysis of high rates of functional cure of HBV at APASL 2019
MONTREAL, February 11, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced it will present analysis of its HBV functional cure data from the ongoing REP 401 study at the 2019 meeting of the Asian Pacific Association for the Study of the Liver (APASL) to be held February 20-24, 2019 in Manila, Philippines.
The REP 401 protocol (NCT02565719) is a randomized, controlled trial assessing the safety and efficacy of REP 2139-Mg and REP 2165-Mg when used in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (peg-IFN) in patients with chronic HBeAg negative HBV infection.
Replicor’s plenary oral presentation will occur during the Autoimmune and Viral Hepatitis Symposium on February 23, 2019 and will include updated mechanistic data as well as the current follow-up analysis after removal of all treatment demonstrating further treatment is no longer required in 85% of patients completing therapy.
Replicor’s presentation from APASL 2019 will be available on the company’s website following their disclosure at the meeting at www.replicor.com/science/conference-presentations. For further information about the 2019 APASL Meeting visit: https://apasl2019manila.org/.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.